These results confirmed the previously predicted 12 TMD structure, and provided new structural details. of the expression of the hDAT variant in Substantia nigra from L-Azetidine-2-carboxylic acid normal subjects and Parkinson disease patients. Total RNA from human Substantia nigra of patients with Parkinson’s disease (PD) or normal subjects (Cont) was obtained commercially, and used to synthesize first strand cDNA (RT+, with RivatraAce; RT-, without RivatraAce). PCR was performed with initial denaturation at 94C for 2 min, followed by 40 cycles of 92C for 30 sec L-Azetidine-2-carboxylic acid and 68C for 2 min with a final extention at 68C for 5 min using Kod-Plus. The primers used were: (hDAT-P#11)/(hDAT-P#10). The PCR products were analyzed by electrophoresis on agarose gel. C: FL hDAT, V: hDATEX6, N: unfavorable control (water as a template), M: DNA marker of 100 bp.(0.66 MB TIF) pone.0011945.s002.tif (649K) GUID:?F02B7452-6117-41A1-8FC1-1E9B730844D0 Table S1: Kinetic analysis of the effect of hDATEX6 on hDAT activity in co-transfected COS-7 cells. COS-7 cells were transfected L-Azetidine-2-carboxylic acid with the full-length (FL) hDAT alone (control) or with numerous amounts of the splice variant hDATEX6. The total amount of DNA for transfection was adjusted with pcDNA3 to 25 g. Uptake assays were carried out by incubating cells with 10 nM [3H]dopamine in the presence of numerous concentrations (0.1C30 M) of unlabelled DA at 37C for 6 min. Specific uptake was determined by subtracting the nonspecific uptake measured in the presence of 100 M cocaine. Values represent the imply SEM for 3 experiments each performed in triplicate. Vmax was expressed as a ratio to the control (FL hDAT alone) value, which was 2.030.55 fmol/g protein/min. *Significantly different from control at P 0.05.(0.03 MB DOC) pone.0011945.s003.doc (31K) GUID:?0CB987B5-322B-4092-8B2B-54E4DBA2525B Abstract Background The transporters for dopamine (DAT) and norepinephrine (NET) are users of the L-Azetidine-2-carboxylic acid Na+- and Cl?-dependent neurotransmitter transporter family SLC6. There is a line of evidence that option splicing results in several isoforms of neurotransmitter transporters including NET. However, its relevance to the physiology and pathology of the neurotransmitter reuptake Rabbit Polyclonal to OR1L8 system has not been fully elucidated. Methodology/Principal Findings We found novel isoforms of human DAT and NET produced by option splicing in human blood cells (DAT) and placenta (NET), both of which lacked the region encoded by exon 6. RT-PCR analyses showed a difference in expression between the full length (FL) and truncated isoforms in the brain and peripheral tissues, suggesting tissue-specific option splicing. Heterologous expression of the FL but not truncated isoforms of DAT and NET in COS-7 cells revealed transport activity. However, immunocytochemistry with confocal microscopy and a cell surface biotinylation assay exhibited that this truncated as well as FL isoform was expressed at least in part in the plasma membrane at the cell surface, even though truncated DAT was distributed to the cell surface slower than FL DAT. A specific antibody to the C-terminus of DAT labeled the variant but not FL DAT, when cells were not treated with Triton for permeabilization, suggesting the C-terminus of the variant to be located extracellulary. Co-expression of the FL isoform with the truncated isoform in COS-7 cells resulted in a reduced uptake of substrates, indicating a dominant L-Azetidine-2-carboxylic acid negative effect of the variant. Furthermore, an immunoprecipitation assay revealed physical interaction between the FL and truncated isoforms. Conclusions/Significance The unique expression and function and the proposed membrane topology of the variants suggest the importance of isoforms of catecholamine transporters in monoaminergic signaling in the brain and peripheral tissues. Introduction Neurotransmitter transporters accumulate extracellular neurotransmitters released from nerve terminals to maintain synaptic clearance, thereby controlling the fine-tuning of neurotransmission [1]. Psychostimulants including cocaine and amphetamines exert their pharmacological effects by acting on monoamine neurotransmitter transporters for.